Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
|
|
- Mabel Leonard
- 5 years ago
- Views:
Transcription
1 Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24 No. 6 Suppl Abstract: The use of aspirin for venous thromboembolism (VTE) prophylaxis after major orthopaedic surgery is controversial. The hypothesis of the present study is that aspirin will decrease the rate of operative site bleeding without increasing thromboembolic events when aspirin is used for VTE prophylaxis after major orthopaedic surgery. A pooled analysis of 14 randomized controlled trials (RCTs) cited by the American College of Chest Physicians (ACCP) guidelines was performed to determine pooled rates of symptomatic deep vein thromboses, pulmonary emboli (PE), fatal PE, and operative site bleeding rates. The VTE rates with aspirin were not significantly different than the rates for vitamin K antagonists (VKA), low molecular weight heparins (LMWH), and pentasaccharides. The operative site bleeding relative risks of VKA, LMWH, and pentasaccharides versus aspirin, are 4.9, 6.4, and 4.2, respectively. A pooled analysis of RCTs supports the use of aspirin for VTE prophylaxis after major orthopaedic surgery. Keywords: venous thromboembolism, orthopaedic surgery, pooled rates Published by Elsevier Inc. Guideline compliance is currently being used as a quality measure of health care in the United Statess. The American College of Chest Physicians (ACCP) has published guidelines for venous thromboembolism (VTE) prevention for multiple medical conditions and surgical procedures that place patients at high risk for venous thromboembolic events, including orthopaedic procedures for total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture surgery (HFS) [1]. Following identification of these VTE high-risk conditions and procedures, ACCP made treatment recommendations for HFS, THA, and TKA. Orthopaedic surgeons have raised numerous concerns about bleeding risks and wound adverse events for THA, TKA, or HFS patients when using ACCP-recommended guidelines, but these concerns have been ignored [2]. From the Department of Orthopaedic Surgery, Park Nicollet Health Services, St. Louis Park, Minnesota; and Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, Minnesota. Submitted January 29, 2009; accepted June 2, No benefits or funds were received in support of the study. Reprint requests: Greg A. Brown, MD, PhD, Department of Orthopaedic Surgery, Park Nicollet Clinic Meadowbrook, Suite E400, 6490 Excelsior Blvd, St. Louis Park, MN Published by Elsevier Inc /09/ $36.00/0 doi: /j.arth The ACCP guidelines purport to use evidence-based medicine principles when evaluating venous thromboembolism prophylaxis after major orthopaedic procedures. However, the methodological flaws incorporated in the ACCP guidelines include: (1) exclusion of randomized controlled trials (RCTs) without venographic outcome assessment; (2) incomplete outcome measures without inclusion criteria requiring measurement of symptomatic deep vein thromboses (DVT), pulmonary emboli (PE), fatal pulmonary emboli, major operative site bleeding complications, and major non-operative site bleeding complications; (3) no quantitative analyses (meta-analysis or pooled analysis) of randomized controlled trials to estimate incidence of symptomatic DVTs, PEs, fatal PEs, major operative site bleeding complications, and major non-operative site bleeding complications; and (4) potential conflicts of interest for multiple members of the guideline drafting committee [3]. The controversy has worsened because the Surgical Care Improvement Project (SCIP) has adopted VTE prophylaxis recommendations for selected surgical procedures (including elective total hip arthroplasty, elective total knee arthroplasty, and hip fracture surgery) from the 2004 ACCP guidelines [4]. The hospital pay-forperformance (P4P) program developed by the Centers for Medicare and Medicaid Services requires hospitals to 77
2 78 The Journal of Arthroplasty Vol. 24 No. 6 Suppl. 1 September 2009 Table 1. Abstracted Data Elements Stratified by VTE Prophylactic Treatment Study/Year Procedure THA TKA Hip Fx Prophylaxis Number of Patients Number of Patients Tested Percent Tested Bauer et al/ Pentasaccharide % Lassen et al/ Pentasaccharide % Turpie et al/ Pentasaccharide % Eriksson et al/ Pentasaccharide % Friedman et al/ LMWH qd % Friedman et al/ LMWH bid % Francis et al/ LMWH % Hull et al/ LMWH % Hamulyak et al/ LMWH % Hull et al/ LMWH preop % Hull et al/ LMWH postop % Leclerc et al/ LMWH % Heit et al/ LMWH low dose % Heit et al/ LMWH mid dose % Heit et al/ LMWH high dose % Fitzgerald et al/ LMWH % Colwell et al/ LMWH Bauer et al/ LMWH % Lassen et al/ LMWH % Turpie et al/ LMWH % Eriksson et al/ LMWH % Friedman et al/ Warfarin % Francis et al/ Warfarin % Hull et al/ Warfarin % Hamulyak et al/ Warfarin % Hull et al/ Warfarin % Leclerc et al/ Warfarin % Heit et al/ Warfarin % Fitzgerald et al/ Warfarin % Colwell et al/ Warfarin Rodgers et al/ Aspirin Rodgers et al/ Aspirin Rodgers et al/ Placebo Rodgers et al/ Placebo follow the SCIP guidelines. The American Academy of Orthopaedic Surgeons (AAOS) has developed VTE guidelines based on pulmonary embolus and bleeding risk stratification [5]. The AAOS guidelines are compatible with the SCIP guidelines if a patient's increased risk for bleeding is documented in the medical record and mechanical prophylaxis measures are used in conjunction with aspirin [6]. Fourteen randomized controlled trials were cited by the 2004 ACCP guidelines. Four classes of pharmacologic agents were studied: (1) aspirin, (2) vitamin K antagonists (VKA), (3) low molecular weight heparins (LMWH), and (4) pentasaccharides. The 14 RCTs evaluated the use of pharmacologic agents for venous thromboembolism prophylaxis after major orthopaedic surgery, including total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture surgery (HFS). The hypothesis of the present study is that aspirin will decrease the rate of operative site bleeding adverse events without increasing the rate of thromboembolic events when
3 Venous Thromboembolism Prophylaxis Brown 79 Positive Venogram Symptomatic DVT Fatal Major Operative Site Major Non-Operative Site Total Major % 0.94% 0.80% 0.30% 1.91% 0.47% 2.38% % 1.28% 0.45% 0.13% 2.92% 1.33% 3.66% % 2.01% 0.40% 0.04% 2.24% 1.49% 2.57% % 0.62% 0.22% 0.46% 2.57% 3.03% % 1.02% 0.52% 0.47% 1.79% 2.26% used for venous thromboembolism prophylaxis after major orthopaedic surgery. Materials and Methods A quantitative systematic review (pooled analysis) of all randomized control trials cited by the ACCP guidelines for VTE prophylaxis after major orthopaedic surgery (THA, TKA, and HFS) was conducted. Nine RCTs compared pharmacologic VTE prophylaxis treatments for total hip arthroplasty [7-15]. Eight RCTs compared pharmacologic VTE prophylaxis treatments for total knee arthroplasty [9,10,13,14,16-19]. Two RCTs compared pharmacologic VTE prophylaxis treatments for hip fracture surgery [13,20]. Three randomized controlled trials included total hip arthroplasty and total knee arthroplasty [9,10,14]. One randomized controlled trial included hip fracture surgery, total hip arthroplasty, and total knee arthroplasty [13]. Fourteen randomized controlled trials were included in the systematic review. Two randomized controlled trials discussed in the ACCP guidelines (but
4 80 The Journal of Arthroplasty Vol. 24 No. 6 Suppl. 1 September 2009 Table 2. Pooled Rates Stratified by VTE Prophylactic Treatment Total Pooled Subjects Venographic Deep Vein Thrombosis Symptomatic Deep Vein Thrombosis Fatal Operative Site Non-Operative Site Total Pentasaccharide % 0.94% 0.80% 0.30% 1.91% 0.47% 2.38% LMWH % 1.28% 0.45% 0.13% 2.92% 1.33% 3.66% Warfarin % 2.01% 0.40% 0.04% 2.24% 1.49% 2.57% Aspirin % 0.62% 0.22% 0.46% 2.57% 3.03% Placebo % 1.02% 0.52% 0.47% 1.79% 2.26% excluded from the ACCP guidelines because the studies did not include venography) were included in the systematic review [7,13]. Each randomized controlled trial was reviewed and data abstracted for the following data elements: (1) screened patients, (2) procedure type (THA, TKA, or HFS), (3) cancelled procedures, (4) pharmacologic VTE prophylactic agent, (5) number of subjects in each subgroup, (6) duration of VTE prophylaxis, (7) number of subjects using graduated compression stockings, (8) use of pneumatic compression devices permitted or number of subjects using pneumatic compression devices, (9) number of subjects using non-steroidal anti-inflammatory drugs (NSAIDs), (10) number of subjects studied with venograms, (11) mean time to venogram (if applicable), (12) positive venograms, (13) positive non-invasive studies, (14) symptomatic deep vein thrombosis (DVTs), (15) pulmonary embolus (PE), (16) fatal pulmonary embolus, (17) major operative site bleeding complications, (18) major non-operative site bleeding complications, and (19) total major bleeding events (Table 5, available online). A pooled data analysis was performed stratified by VTE prophylaxis agent (Table 1). The rates of venographic DVT, symptomatic DVT, PE, fatal PE, major operative site bleeding events, and major non-operative site bleeding events were calculated based on the pooled data (Table 2). Chi-square tests were used to compare binomial pooled rates. Chi-square 2 2 tests require all cells to be 5 or greater. If a cell value was less than 5, Fisher's exact test was used. Significance level was Fifteen statistical comparisons were conducted (aspirin versus pentasaccharides, LMWH, and VKA across five rates: symptomatic DVT, PE, fatal PE, major operative site bleeding, and major non-operative site bleeding) (Table 3). A Bonferroni correction for statistical significance was performed. The corrected significance level is 0.05/15 = Binomial relative risks with confidence intervals (CI) were calculated for each comparison (Table 4). Results The abstracted data is stratified by randomized controlled trial (Table electronically published). The abstracted data is stratified by VTE prophylactic agent (Table 1). The pooled incidence of venographic deep vein thromboses, symptomatic deep vein thromboses, pulmonary emboli, fatal pulmonary emboli, major operative site bleeding complications, and major non-operative site bleeding complications are listed in Table 2. Chi-square tests for binomial variables (2 2) were used to statistically compare rates. The p-values for each statistical comparison are reported in Table 3. The following significant differences were observed: (1) symptomatic DVT rates aspirin versus VKA (P = ); and (2) operative site bleeding/wound adverse events aspirin versus VKA (P = ), aspirin versus LMWH (P = 1.0v10-35 ), aspirin versus pentasaccharides (P = ). With the Bonferroni correction (α = ), the difference in fatal pulmonary embolus rates between aspirin and VKA is not statistically significant (Chi-square P =.017, Fisher's exact test P =.019). The non-operative bleeding event rate comparisons are included in Table 3 for scientific completeness, but the statistical comparisons are not valid (see Discussion section). The two proportions relative risks and confidence intervals for symptomatic deep vein thromboses, pulmonary emboli, fatal pulmonary emboli, major operative site bleeding complications, and non-operative bleeding complications comparing (1) pentasaccharide/aspirin; (2) LMWH/aspirin; and (3) warfarin/aspirin are reported in Table 4. The non-operative bleeding event relative risks and confidence intervals are included in Table 4 for scientific completeness, but the statistical comparisons are not valid (see Discussion section). Discussion This quantitative systemic review (pooled analysis) of fourteen randomized controlled trials for venous Table 3. Chi-Square P-Values for Pooled Rates Comparing Aspirin to Pentasaccharides, LMWH, and Warfarin (Bonferroni correction 0.05/15 = ) Symptomatic Deep Vein Thrombosis Fatal Operative Site Non-Operative Site Pentasaccharide vs ASA E E-14 LMWH vs ASA E E-08 Warfarin vs ASA 3.5E E
5 Venous Thromboembolism Prophylaxis Brown 81 Table 4. Binomial s and s of Pentasaccharides, LMWH, and Warfarin Compared to Aspirin Symptomatic Deep Vein Thrombosis Fatal Operative Site Non- Operative Site Pentasaccharide vs ASA LMWH vs ASA Warfarin vs ASA thromboembolism (VTE) prophylaxis after major orthopaedic surgery finds no significant difference in clinically-relevant VTE outcomes, except vitamin K antagonists have a higher rate of symptomatic DVTs compared to aspirin. Inclusion of the Embolism Prevention (PEP) trial [13] negates the ACCP guideline's statement that there is no evidence that aspirin is effective in reducing VTE events after major orthopaedic surgery. In fact, the use of vitamin K antagonists, low-molecular-weight heparins, and pentasaccharides after major orthopaedic surgery significantly increase the risk of operative site bleeding events, without reducing clinically-relevant symptomatic deep vein thrombosis, pulmonary embolism, and fatal pulmonary embolism rates. This pooled analysis is transparent, quantitative, and includes complete clinical outcomes. However, pooled analysis results have certain limitations and biases. Because each RCT study design may differ, the outcomes are not always comparable. The PEP trial did not delineate major or minor bleeding events. However, 182 of 224 non-operative site bleeding events did not require a transfusion (placebo 122 of 154). All bleeding events were included in the pooled analysis because events could not be differentiated between major and minor. Also, the PEP trial is the only RCT comparing an active comparator to placebo. The remaining 13 RCTs compare two active comparators. The generalizability of the pooled analysis is limited by the inclusion/exclusion criteria of each RCT. However, all trials are prospective and randomized, so a selection bias should not be present. Although pooled analyses have limitations, a meta-analysis could not be performed because there are no RCTs comparing aspirin to VKAs, LMWHs, or pentasaccharides. Evidence-based medicine requires inclusion of all clinically-relevant outcomes. The ACCP guidelines minimize the importance of symptomatic DVTs, PEs, fatal PEs, and operative site bleeding complications. Level I evidence for therapeutic studies requires randomized controlled trials or systematic reviews of randomized controlled trials with homogeneous studies. There is no requirement for specific measurement techniques, such as venography. In fact, venographic testing over-estimated the effectiveness of LMWH as noted by O'Donnell et al [21]. The ACCP guidelines note we place a relatively low value on the prevention of venographic thrombosis, and a relatively high value on minimizing bleeding complications [1]. However, because the ACCP guidelines use narrative review of the RCTs, the process by which VTE and bleeding events are weighted is not transparent. The ACCP guidelines do not appear to be consistent with their noted relative value weighting. No clinical evidence is presented in the ACCP guidelines that post-thrombotic syndrome is a significant clinical problem associated with THA, TKA, or HFS. The ACCP inclusion criteria specify DVT outcome assessment with contrast venography or duplex ultrasonography (DUS). The basis for these strict inclusion criteria is the hypothesized link between asymptomatic DVTs and post-thrombotic syndrome with its associated morbidity. Without a Level 1 prognostic outcome study documenting post-thrombotic syndrome after THA, TKA, and HFS, the ACCP drafting committee has reduced their guidelines to expert opinion. The Embolism Prevention (PEP) trial is the only adequately-powered randomized controlled trial to observe a 1% difference (1% vs 2%) in symptomatic DVTs after major orthopaedic surgery (each subgroup requires 2316 subjects). After excluding the PEP trial, the ACCP guidelines recommend against the use of aspirin alone (Grade 1A). The recommendation against aspirin use is incorrect because the PEP trial is the highestpowered randomized controlled trial studying VTE prophylaxis after major orthopaedic surgery. The ACCP systematic review lacks scientific rigor. The ACCP narrative review argues that the PEP trial has methodological flaws. The ACCP review does not define an RCT quality assessment method. Without a formal study quality assessment, there is no basis for excluding the PEP trial. Cochrane Reviews have greater methodological rigor than other reviews [22]. The Cochrane Review for VTE prophylaxis after hip fractures noted that prior research in the prophylaxis of DVT and thromboembolism using interventions under review has many shortcomings. many of the above [study design
6 82 The Journal of Arthroplasty Vol. 24 No. 6 Suppl. 1 September 2009 problems] are avoided by the recent PEP trial, which can be considered a good example to follow [23]. The Scottish Intercollegiate Guidelines Network endorses the PEP study findings and recommends All patients with hip fracture should receive aspirin (150 mg orally, started on admission and continued for 35 days) unless contraindicated [24]. Other guideline organizations endorse the PEP study findings. An additional inconsistency of the ACCP guidelines is that no RCTs using vitamin K antagonists for hip fracture surgery are cited, but the guidelines support the use of VKAs for hip fracture surgery while dismissing the highest-powered randomized controlled trial of aspirin (PEP trial) and excluding the use of aspirin for hip fractures. Evidence-based medicine is intended to empower the patient's informed preference [25]. Therefore, EBM guidelines must include a transparent risk/benefit analysis of the clinical risks and benefits of any intervention. Without a meta-analysis or pooled-analysis, there is no quantitative comparison of the relative risks of aspirin, warfarin, LMWH, or pentasaccharides and the patient cannot express an informed preference. The non-operative site bleeding event rates are not comparable. Aspirin is the only pharmacologic agent compared to placebo [13]. The non-operative site bleeding event rate for aspirin was 2.57%. The nonoperative site bleeding event rate for placebo was 1.79%. The non-operative site bleeding event rate attributable to aspirin is 0.78%. This rate is lower than the nonoperative site bleeding event rates for LMWH and VKA and higher than pentasaccharides. Additionally, 182 of the 218 (83.4%) non-operative site bleeding events were gastrointestinal (GI) bleeding events that did not require a transfusion so the clinical severity of the GI bleeding events is unknown. Therefore, the differences between non-operative site bleeding event rates are reported for scientific completeness, but the significance of these findings is questionable. The application of evidence-based medicine to an individual patient requires not only a review of the clinical evidence, but an assessment of the generalizability of the clinical evidence to the individual patient. The AAOS guidelines risk stratify the patients according to VTE risks and bleeding risks to individualize evidencebased medical care [5], but the ACCP guidelines provide not risk stratification recommendations. Six of seven members of the ACCP drafting committee have listed potential conflicts of interest with pharmaceutical companies [3]. When CMS adopted the SCIP guidelines for their pay-for-performance program, CMS had an obligation to perform due diligence before accepting the ACCP guidelines and SCIP guidelines for implementation. Given the potential conflicts of interest of the ACCP drafting committee, the acceptance of the PEP trial as a model trial for VTE prophylaxis, and the cost-effectiveness of aspirin, CMS must reassess the SCIP guidelines. John Abramson has described the commercial bias on the scientific evidence' that informs medical decisions [26]. National guidelines, such as the SCIP guidelines, require a drafting committee without potential conflicts of interest. Multimodal VTE prophylaxis is safe and effective. The ACCP guidelines recommend against the use of aspirin alone (Grade 1A) [1]. However, orthopaedic surgeons are not using aspirin alone, but using aspirin as part of multimodal VTE prophylaxis including intermittent pneumatic compression devices and early mobilization [27]. Multimodal VTE prophylaxis allows the minimization of bleeding risks by using aspirin in lower VTE risk patients. The ACCP and SCIP guidelines do not endorse multimodal VTE prophylaxis. Multimodal VTE prophylaxis with regional anesthesia, pneumatic compression, and aspirin is safer than potent anticoagulants. Sharrock et al [28] conducted a metaanalysis of VTE prophylaxis evaluating three month allcause mortality comparing potent anticoagulants (Group A: low-molecular-weight heparin, ximelagatran, fondaparinux, or rivaroxaban), multimodal prophylaxis (Group B: regional anesthesia, pneumatic compression, and aspirin), and warfarin (Group C). The random effects meta-analysis found that the relative risk of three month all-cause mortality comparing Group A to Group B was 2.48 ( confidence interval , P b.01) and comparing Group C to Group B was 2.29 ( confidence interval , P =.03). Alternatively stated, the three month all-cause mortality of patients receiving potent anticoagulants or warfarin was more than two-fold higher than patients receiving multimodal VTE prophylaxis with aspirin. If evidence-based medicine is to be credible, a systematic review must be transparent, quantitative, and include all evidence. The present study supports the use of aspirin for venous thromboembolism prophylaxis after major orthopaedic surgery. Appendix A. Supplementary Data Supplementary data associated with this article can be found, in the online version, at doi: /j.arth References 1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126:338S. 2. Callaghan JJ, et al. Prophylaxis for Thromboembolic Disease: Recommendations from the American College of Chest Physicians - Are They Appropriate for Orthopaedic Surgery? J Arthroplast 2005;20: American College of Chest Physicians. Financial disclosures. Chest 2004;126:167S. 4. Medicare Quality Improvement Community. Surgical care improvement project (SCIP) VTE prophylaxis options for surgery. [Edited]
7 Venous Thromboembolism Prophylaxis Brown American Academy of Orthopaedic Surgeons. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. [Edited] www. aaos.org/research/guidelines/pe_summary.pdf, Haralson RH. Clearing up the confusion with VTE and/or PE prophylaxis guidelines. AAOS Now; p. 11. [Edited, 11]. 7. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone Jt Surg Am 1999;81-A: Francis CW, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. J Bone Jt Surg Am 1997; 79-A: Hamulyak K, Lensing AWA, van der Meer J, et al. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 1994; 74: Hull R, et al. A comparison of subcutaneous low-molecularweight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329: Hull RD, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison. Arch Int Med 2000;160: Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet 2002;359: Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Embolism Prevention (PEP) trial. Lancet 2000;355: RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Jt Surg Am 1994;76-A: Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet 2002;359: Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345: Fitzgerald RH, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Jt Surg Am 2001;83-A: Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study. Thromb Haemost 1997; 77: Leclerc JR, et al. Prevention of venous thromboembolism after knee arthroplasty: A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Int Med 1996; 124: Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345: O'Donnell M, Linkins L-A, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: A systematic review. Arch Int Med 2003;163: Jadad AR, Cook DJ, Jones A, et al. Methodology and reports of systematic reviews and meta-analyses: A comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998;280: Handol HHG, Farrar MJ, McBirnie J, et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. [Edited]Cochrane Database Syst Rev Scottish Intercollegiate Guidelines Network (SIGN). Prevention and Management of Hip Fracture in Older People. Edinburgh: SIGN Executive, Royal College of Physicians; p. 14. [Edited]. 25. Fisher CG, Wood KB. Introduction to and techniques of evidence-based medicine. Spine 2007;32:S Abramson J. Overdosed America: The Broken Promise of American Medicine. New York: HarperCollins; 2004 [Edited]. 27. Dorr LD, Gendelman V, Maheshwari AV, et al. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Jt Surg Am 2007; 89-A: Sharrock NE, Della Valle AG, Go G, et al. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res 2008;466:714.
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More information1/27/2016. Disclosure. Goals. The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology
The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationPage: 1 of 14. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Subject: Post-Surgical Outpatient Use of Limb Page: 1 of 14 Last Review Status/Date: March 2015 Post-Surgical Outpatient Use of Limb Compression Devices for Venous Description Patients undergoing major
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationProtocol. Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for (10128) (Formerly Outpatient Use of Limb Pneumatic Compression Devices for ) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationEffect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention
European Heart Journal Supplements (2008) 10 (Supplement C), C8 C13 doi:10.1093/eurheartj/sun004 Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of
More informationMeasurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI
Measurement and Improvement of Quality of Cardiovascular Care DR : DEHESTANI Hospitals For hospitals in the United States, measures of cardiovascular care mandated by the Joint Commission have recently
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationWhat evidence exists that describes the efficacy of mechanical prophylaxis for venous thromboembolism (VTE) in adult surgical patients?
July 2015 Rapid Review Evidence Summary McGill University Health Centre: Division of Nursing Research and MUHC Libraries What evidence exists that describes the efficacy of mechanical prophylaxis for venous
More informationProphylaxis for Venous Thromboembolism Following Total Knee Arthroplasty: A Survey of Korean Knee Surgeons
Original Article Knee Surg Relat Res 2016;28(3):207-212 http://dx.doi.org/10.5792/ksrr.2016.28.3.207 pissn 2234-0726 eissn 2234-2451 Knee Surgery & Related Research Prophylaxis for Venous Thromboembolism
More informationDisclosures. Venous Thromboembolism Prophylaxis: What every orthopaedic surgeon needs to know. Published Guidelines
Venous Thromboembolism Prophylaxis: What every orthopaedic surgeon needs to know Paul F. Lachiewicz, MD Chapel Hill Orthopedic Surgery & Sports Medicine Consulting Professor Duke Orthopaedic Surgery Disclosures
More informationAbbreviations: ACCP American College of Chest Physicians; CI confidence interval; CPMP Committee for Proprietary Medicinal Products
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points* Alexander G.G. Turpie, MD; Kenneth A. Bauer, MD; Bengt
More informationVenous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?
TRAUMA AND ORTHOPAEDIC SURGERY Ann R Coll Surg Engl 2016; 98: 538 542 doi 10.1308/rcsann.2016.0202 Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14, 09/15/15,09/21/17. THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY REVISED DATE: 06/26/14, 09/15/15,09/21/17. PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationBest Practice for Deep Vein Thrombosis Prevention: A Research Review. Pamela Dusseau Carly Macklin Natalie Russell Danielle Williams
Running Head: BEST PRACTICE FOR DEEP VEIN THOMBOSIS PREVENTION 1 Best Practice for Deep Vein Thrombosis Prevention: A Research Review Pamela Dusseau Carly Macklin Natalie Russell Danielle Williams Ferris
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 15 November 2007 CPMP/EWP/707/98 Rev.1 corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR PROPHYLAXIS
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationPost-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationPrevention of VTE in Orthopedic Surgery Patients
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationAJO. An Original Study. Ashley Levack, MAS, Atul F. Kamath, MD, and Jess H. Lonner, MD
An Original Study Ashley Levack, MAS, Atul F. Kamath, MD, and Jess H. Lonner, MD dvances in surgical technique, patient selection, and prosthetic design for patellofemoral arthroplasty (PFA) have generated
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 4.3 NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Measure Set: Venous Thromboembolism (VTE) Set Measure Set I #: Performance Measure Name: Intensive
More informationMEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION REVISED DATE: 06/26/14, 10/15/15, 06/16/16, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More information2/22/2018. Goals. What are We Concerned About?
DVT Prophylaxis - Concerns in Foot and Ankle Pathology CSFA Tampa, Feb. 2018 STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR THE UNIVERSITY OF
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationSymptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study
IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after
More informationNearly half of orthopedic surgery patients do. Prevention of venous thromboembolism in the orthopedic surgery patient
STEVEN B. DEITELZWEIG, MD SYLVIA C. McKEAN, MD ALPESH N. AMIN, MD, MBA DANIEL J. BROTMAN, MD AMIR K. JAFFER, MD ALEX C. SPYROPOULOS, MD Prevention of venous thromboembolism in the orthopedic surgery patient
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationCopyright Restricted. Orthopedic surgery carries a high risk of venous
Practice Patterns in the Use of Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty Insights From the Multinational Global Orthopaedic Registry (GLORY) Richard J. Friedman, MD, FRCSC, Alexander
More informationJapanese Deep Vein Thrombosis
Japanese Deep Vein Thrombosis and Pulmonary Embolism after Total Knee Arthroplasty Artificial joint and cartilage implantation center, Kitasato institute hospital, Kitasato university Yasunori Tsukimura
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Postsurgical Home Use of Limb Compression Devices Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Postsurgical Home Use of Limb Compression
More informationPostsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Policy Number: 1.01.28 Last Review: 4/2018 Origination: 4/2013 Next Review: 4/2019 Policy Blue Cross and Blue
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationVenous thromboembolism (VTE) is a common complication
Prevention of Venous Thromboembolism in Surgical Patients Giancarlo Agnelli, MD Abstract Venous thromboembolism (VTE) is a common complication of surgical procedures. The risk for VTE in surgical patients
More informationPRIMARY TOTAL KNEE & HIP
Clinical Guideline Version 2.0 Title: PRIMARY TOTAL KNEE & HIP Venous ThromboEmbolic (VTE) Guideline Target Audience: thopedic Surgeons and their Advanced Practice Practitioner partners; Hospitalists,
More informationComparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project
Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project Dr. Jonathan Laxton, FRCPC, R5 GIM University of Manitoba
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More informationNone. Who uses IV antibiotics before simple knee arthroscopies? 3/9/2018. Anticoagulants or Antibiotics Are they Necessary for Simple Knee Scopes?
Anticoagulants or Antibiotics Are they Necessary for Simple Knee Scopes? Rachel M. Frank, MD Assistant Professor, Department of Orthopaedic Surgery Sports Medicine, Cartilage Restoration, and Shoulder
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationFINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY
Arthroplasty Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events FINDINGS FROM THE GLOBAL ORTHOPAEDIC
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationSociety of Trauma Nurses TraumaCon 03/22/2018
Prophylaxis Against Venous Thromboemblism (VTE) in Pediatric Trauma Society of Trauma Nurses TraumaCon 03/22/2018 Arash Mahajerin, MD, MSCr Hematology, CHOC Children s Specialists Orange, CA Disclosure
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationNew ACCP antithrombotic guidelines: overview & critical appraisal
New ACCP antithrombotic guidelines: overview & critical appraisal Dr. A.T. Cohen Honorary Consultant Vascular Physician King's College Hospital, London, UK ACCP 2012 New ACCP antithrombotic guidelines:
More informationPostsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Policy Number: 1.01.28 Last Review: 4/2019 Origination: 4/2013 Next Review: 4/2020 Policy Blue Cross and Blue
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationThromboembolism and cancer: New practices. Marc Carrier
Thromboembolism and cancer: New practices Marc Carrier Marc Carrier Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board Leo Pharma, BMS No relevant
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationDeep vein thrombosis leads to catastrophic RECONSTRUCTIVE
RECONSTRUCTIVE Deep Venous Thrombosis Practice and Treatment Strategies among Plastic Surgeons: Survey Results George Broughton, II, M.D., Ph.D. Jose L. Rios, M.D. Rod J. Rohrich, M.D. Spencer A. Brown,
More informationIncidence of Symptomatic Pulmonary Embolism in Spinal Surgery
Incidence of Symptomatic Pulmonary Embolism in Spinal Surgery Chatupon Chotigavanichaya MD*, Monchai Ruangchainikom MD*, Choompon Piyavanno MD*, Ekkapoj Korwutthikulrangsri MD*, Sirichai Wilartratsami
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationThe compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery
DOI 10.1186/s40064-016-2724-1 RESEARCH The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery Yuan Gao 1, Anhua Long 2,3, Zongyan Xie
More informationDeep Vein Thrombosis Prevention in Total Knee Arthroplasty. A Review -
International Journal of Orthopedics: Research & Therapy Review Article Deep Vein Thrombosis Prevention in Total Knee Arthroplasty. A Review - Julio Cesar Gali* Faculty of Medical Science and Health Catholic
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationVenous Thromboembolism Prophylaxis
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Seventh Edition August 2010 The information contained in this ICSI Health Care Guideline is
More informationThe effect of aspirin and low-molecularweight heparin on venous thromboembolism after knee replacement
S. S. Jameson, P. N. Baker, S. C. Charman, D. J. Deehan, M. R. Reed, P. J. Gregg, J. H. Van der Meulen From London School of Hygiene and Tropical Medicine, London, United Kingdom S. S. Jameson, MRCS, Research
More information